Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eton Pharmaceuticals (ETON) Cost of Revenue (2019 - 2025)

Historic Cost of Revenue for Eton Pharmaceuticals (ETON) over the last 7 years, with Q3 2025 value amounting to $14.6 million.

  • Eton Pharmaceuticals' Cost of Revenue rose 26310.29% to $14.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.5 million, marking a year-over-year increase of 9454.37%. This contributed to the annual value of $15.6 million for FY2024, which is 4743.41% up from last year.
  • Eton Pharmaceuticals' Cost of Revenue amounted to $14.6 million in Q3 2025, which was up 26310.29% from $7.0 million recorded in Q2 2025.
  • Over the past 5 years, Eton Pharmaceuticals' Cost of Revenue peaked at $14.6 million during Q3 2025, and registered a low of $174000.0 during Q2 2021.
  • Moreover, its 5-year median value for Cost of Revenue was $2.3 million (2023), whereas its average is $3.1 million.
  • In the last 5 years, Eton Pharmaceuticals' Cost of Revenue soared by 147758.62% in 2022 and then plummeted by 7718.82% in 2025.
  • Eton Pharmaceuticals' Cost of Revenue (Quarter) stood at $372000.0 in 2021, then skyrocketed by 474.73% to $2.1 million in 2022, then surged by 72.26% to $3.7 million in 2023, then surged by 40.4% to $5.2 million in 2024, then surged by 182.42% to $14.6 million in 2025.
  • Its last three reported values are $14.6 million in Q3 2025, $7.0 million for Q2 2025, and $675000.0 during Q1 2025.